Salmeterol-Fluticasone Combined Inhaled Therapy for Non-cystic Fibrosis Bronchiectasis

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2011
The objective of this study is to assess the efficacy and safety of Salmeterol-Fluticasone (ICS and LABA)combined inhaled therapy for non-cystic fibrosis(non-CF)bronchiectasis patients with chronic airflow obstruction. Moreover, subgroup analysis is performed to explore which populations of bronchiectasis patients this treatment is suitable for.
Epistemonikos ID: d2cae97f3806ccb7e53b814b0e34669ef74157fd
First added on: May 13, 2024